Endothelial Dysfunction - The First Step Towards Coronary Disease

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

More than a quarter of a century ago Robert Furchgoldltt demonstrated that removing the endothelial layer from the isolated aorta of a rabbit prevents normal relaxation in response to acetylcholine.1 The ability of the endothelium to elicit relaxation was soon extended to more relevant physiological stimuli (adenosine triphosphate, bradykinin and serotonin).2,3 The endothelial cells cause arterial relaxation by releasing a powerful vasoactive substance(s) that diffuses to the underlying layers of vascular smooth muscle and thus was termed endothelium-derived relaxing factor (EDRF). EDRF stimulates the activity of soluble guanylyl cyclase with the subsequent production of cyclic guanosine monophosphate (cyclic GMP) in the vascular smooth-muscle cells; it is also avidly scavenged by superoxide anions.4,5 These findings led Robert Furchgott and Louis Ignarro to the proposal that EDRF is nitric oxide (NO),6,7 a hypothesis that was proved correct by Salvador Moncada.8 Further investigations have identified many components of the pathway producing NO, from the stimulation of muscarinic (and other) receptors on the endothelial cells to the eventual activation of an enzyme, endothelial NO synthase (eNOS or NOS3), that transforms L-arginine into NO. When inhibitors of the enzymes involved in the pathway became available, it soon appeared that NO is involved in many aspects of biology.8 However, in the years that followed it also became evident that endothelial cells can affect the tone of the underlying smooth muscle in more than one way.9–15 This article focuses on NO because its reduced production characterises endothelial dysfunction, which is the first step (at least in the author’s mind) in the long chain of events that leads to atherosclerosis and coronary disease.9,16–19

The Protective Role of the Endothelium

The release of NO plays an essential role in the protection exerted by the endothelial cells against coronary disease. Indeed, the endothelial mediator not only prevents abnormal constrictions (vasospasm) of the coronary arteries, but also inhibits the aggregation of platelets, the expression of adhesion molecules at the surface of the endothelial cells and, hence, the adhesion and penetration of white blood cells (macrophages) and the release and action of the vasoconstrictor and mitogenic peptide endothelin-1 (see Figure 1). The protective release of NO is exacerbated by the local presence of factors involved in the coagulation of the blood, in particular the formation of thrombin and the aggregation of platelets. If this protective role of NO fails, the stage is set for the inflammatory response that will eventually lead to the formation of atherosclerotic plaques.9,16–22

The protective role played by the endothelial cells against unwanted coagulation has been demonstrated repeatedly not only in vitro3,23–26 but also in vivo.27 If constricted isolated animal or human coronary arteries with healthy endothelium are exposed to thrombin or aggregating platelets, they relax immediately because of the endothelial release of NO. If the endothelium has been removed, this relaxation is no longer observed, and the aggregating platelets induce vigorous constrictions as a result of their liberation of thromboxane A2 and serotonin (5-hydroxytryptamine). When aggregating human platelets were added to the solution, vasospasm occurred in the arteries without endothelium. Thus, the healthy endothelium appears to protect blood vessels from vasospasm when they are threatened by aggregating platelets, thrombin or the arrival of a thrombus.

The two most important substances released by aggregating platelets that trigger the activation are serotonin and adenosine diphosphate (ADP). The former is dominant and stimulates 5-HT1D serotonergic receptors of the endothelial cell membrane. ADP is a relatively minor contributor that acts on P2y purinergic receptors. These two products trigger distinct signalling cascades in the endothelial cells (see Figure 1). The stimulation of serotonergic receptors (and of those for thrombin) is coupled to the activation of eNOS through pertussis toxin-sensitive Gi-proteins, and purinergic receptors follow a Gq-dependent cascade.25-29

If platelet aggregation were to occur in a coronary artery with a normal endothelium, the release of serotonin (and ADP) and the local initiation of the coagulation cascade (with the production of thrombin) would become a strong signal for the endothelial cells to release NO. The endothelial mediator will not only cause the underlying smooth-muscle cells to relax, allowing the beginning aggregate to be flushed away by the flow of blood, but will also exert, hand in hand with prostacyclin, which is also released, an immediate feedback inhibition of the platelet aggregation process. Under normal conditions, if the endothelial barrier is interrupted by injury, the aggregating platelets can move to the immediate vicinity of the vascular smooth-muscle cells. The thromboxane A2 and serotonin that they release cause constriction, which initiates the vascular phase of haemostasis. Such endothelium-dependent responses to platelets are not present equally in all blood vessels, but are most prominent in the coronary and cerebral circulations. The ability of endothelial cells to release NO in response to aggregating platelets and other stimuli can be modulated in the intact organism by a number of chronic factors in both positive and negative ways. Their inability to do so sufficiently has become a hallmark and indeed a predictor of cardiovascular disease.

Positive Modulation of Endothelial Responsiveness

Both acute and chronic increases in flow and the resulting increasing force of shearing (shear stress) of the blood on the endothelial cells augment the release of EDRF.30–34 In the coronary circulation the effect of shear stress involves the local production of the autacoid bradykinin, which stimulates the release of NO through a Gq-dependent mechanism.25–29,35,36 The chronic effect of shear stress involves an upregulation of eNOS in the endothelial cells, leading to a greater release of NO. This then explains the repeatedly demonstrated beneficial effects of regular exercise on endothelial function.37–41

In ovariectomised animals the reintroduction of physiological levels of 17 β-estradiol potentiates endothelium-dependent relaxation of the isolated arteries.42 The potentiating effect of oestrogens on the release of NO has been confirmed repeatedly and involves both non-genomic and genomic (upregulation of eNOS) effects. In the coronary artery the potentiation is seen only with stimuli that activate Gi-coupled receptors on the endothelial cells.43 It is counteracted by progesterone.43 The potentiating effect of oestrogens on the release of NO by the endothelium helps to explain why women are protected against coronary disease, at least until the age of menopause. The opposing effects of oestrogens and progesterone on endothelial function may help to explain why hormone replacement therapy has not always had the expected beneficial effect on the occurrence of cardiovascular events.

Dietary factors also affect the ability of endothelial cells to release NO. Thus, the chronic intake of ω3-unsaturated fatty acids augments the endothelium-dependent relaxation of isolated coronary arteries to aggregating platelets and other stimuli.44–47 This augmentation of endothelial function is also observed in the human circulation. The same holds true for the intake of polyphenols, whether present in red wine, green tea or dark chocolate.48–56

Negative Modulation of Endothelial Responsiveness

Unfortunately, with increasing age the endothelium has a reduced capacity to release NO, as has been demonstrated repeatedly both in animals and in people.18,57 There is an overwhelming amount of data demonstrating that smoking, both chronically and acutely, inhibits the expression of eNOS and thus the ability of the endothelium to release NO. More recently, it also became obvious that chronic exposure to polluted air and intermittent hypoxia (obstructive sleep apnoea) reduce endothelium-dependent responsiveness.58,59

Dietary factors can have a negative impact on endothelial function. Thus, in animals a chronic hypercholesterolaemic diet blunts endothelium-dependent responsiveness.60,61 In humans hypercholesterolaemia is associated with endothelial dysfunction, and normalisation of the cholesterol level (e.g. following treatment with statins) in the blood restores the response.62,65 These observations are in line with the studies demonstrating that obese humans exhibit reduced responses to endothelium-dependent vasodilators.66

Diseases that constitute major risk factors of coronary disease are also accompanied by an abnormal function of the endothelium. Thus, diabetes has long been associated with impaired arterial endothelium-dependent relaxation.67 Likewise, the endothelium-dependent relaxation is reduced in isolated arteries from different animal models of hypertension, as is the response of endothelium-dependent vasodilators in hypertensive humans.68–71 However, both in diabetes and in hypertension, the reduced endothelium-dependent relaxation/vasodilatations are not due solely to a diminished release of NO but also to the augmented production by the endothelial cells of vasoconstrictor prostanoids.12

Regenerated Endothelial Cells

Under normal conditions mature endothelial cells remain quiescent for many years because they are in mutual physical contact (contact inhibition). However, their turnover is accelerated by the cardiovascular risk factors mentioned previously. Eventually, these cells undergo apoptosis, are removed by circulating blood and are replaced rapidly by regenerated endothelial cells. It is still uncertain what the exact contribution in this regeneration process is of neighbouring cells freed of the contact inhibition and circulating endothelial progenitor cells.74–78

Whatever their origin, regenerated endothelial cells appear to be dysfunctional. This conclusion is based on experiments performed in porcine coronary arteries. In this preparation, one month after in vivo balloon denudation of the endothelium of part of the artery a total relining of the endothelial surface occurred. However, rings with endothelium of the previously denuded part of the artery did not fully relax to aggregating platelets, serotonin or thrombin, and the remaining relaxation was no longer inhibited by pertussis toxin, suggesting that Gi-protein- mediated responses are defective in regenerated endothelial cells.27,29,79 In contrast, relaxation evoked by agonists that employ the Gq-signalling cascade was normal, implying a selective dysfunction of the Gi-dependent responses in regenerated endothelial cells.

This selective dysfunction was reduced by the chronic intake of ω3-unsaturated fatty acid and exacerbated by a chronic hypercholesterolaemic diet, which resulted in the occurrence of typical atherosclerotic lesions in the area of previous denudation.46,60 These observations prompted the conclusion (at least by the author and his colleagues) that the dysfunction of regenerated endothelial cells is the first step allowing the atherosclerotic process.

Further work to analyse the molecular mechanisms underlying the dysfunction of regenerated endothelial cells was performed on primary cultures (with all the limitations of cell culture studies, in terms of relevance to the intact organism) derived from either regenerated or native endothelium.78,80–82 The cultures derived from regenerated endothelium had the appearance and markers of senescent cells, had a reduced expression and activity of eNOS, produced more oxygen-derived free radicals, took up more modified low-density lipoprotein cholesterol (LDL) and generated more oxidised LDL (oxLDL). However, the presence of Gi-proteins was comparable in the two cell types. Those phenotypic and functional changes are in line with the genomic changes observed in cultures of regenerated endothelial cells. Moderately increased concentrations of oxLDL reduce the production of EDRF by endothelial cells and inhibit endothelium-dependent relaxations to serotonin,83,84 hence the conclusion that the augmented presence in regenerated endothelial cells of oxLDL is the cause of the selective loss in Gi-protein-mediated responses and the resulting inability to respond to serotonin and thrombin, setting the atherosclerotic process in motion (see Figure 2).

It would be naïve to claim that this is the only negative effect of oxLDL that obviously plays a central role in the atherosclerotic process.85–87 It has a direct inhibitory effect on the expression and activity of eNOS.88,89 It also enhances the activity of arginase, which competes with NO for the common substrate arginine.90–92 A greater production of superoxide anions will reduce the bioavailability of NO and increase the levels of peroxynitrite.89,93–95 A number of other genomic factors and endogenous mediators may accelerate or contribute to the atherosclerotic process.78,96–99 However, the ultimate result is that the endothelial cells cannot produce enough NO in response to platelets and thrombin and allow the inflammatory reaction leading to atherosclerosis.100


Normal endothelial cells respond to aggregating platelets and thrombin by releasing NO. This key endothelial mediator relaxes the underlying vascular smooth-muscle cells and immediately inhibits the platelet aggregation process. It also inhibits the expression of adhesion molecules, and thus the adhesion and penetration of white blood cells. NO prevents the growth and proliferation of vascular smooth-muscle cells, reduces the production and action of endothelin-1 production and limits the oxidation of LDL. Ageing, insults to the coronary endothelial layer (including lifestyle factors such as the Western diet, pollution and smoking) or diseases facilitating cardiovascular events (diabetes and hypertension) create a vicious circle in which damaged endothelial cells undergo apoptosis and new ones are regenerated. However, the function of these regenerated cells differs from that of native endothelial cells, leading to accelerated cell senescence and abnormal production of NO and facilitating the inflammatory reaction leading to atherosclerosis.


  1. Furchgott RF, Zawadzki JV, The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine, Nature, 1980;288:373–6.
  2. De Mey JG, Claeys M, Vanhoutte PM, Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery, J Pharmacol Exp Ther, 1982;222:166–73.
  3. Cohen RA, Shepherd JT, Vanhoutte PM, Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets, Science, 1983;221:273–4.
  4. Rubanyi GM, Lorenz RR, Vanhoutte PM, Bioassay of endothelium-derived relaxing factor(s) Inactivation by catecholamines, Am J Physiol, 1985;249:H95–H101.
  5. Rubanyi GM, Vanhoutte PM, Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factors, Am J Physiol, 1986;250:H822–H827.
  6. Furchgott RF, Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM (ed) Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium, Raven Press: New York, 1988:401–14.
  7. Ignarro LJ, Byrns RE, Wood KS, Biochemical and pharmacological properties of endothelium-derived relaxing factor and its similarity to nitric oxide radical. In: Vanhoutte PM (ed), Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium, Raven Press: New York, 1988:427–36.
  8. Moncada S, Nitric oxide in the vasculature:physiology and pathophysiology, Ann NY Acad Sci, 1997;811:60–67.
  9. Vanhoutte PM, The endothelium: modulator of vascular smooth-muscle tone, N Engl J Med, 1988;319:512–13.
  10. Furchgott RF, Vanhoutte PM, Endothelium-derived relaxing and contracting factors, FASEB J, 1989;3:2007–17.
  11. Lüscher TF, Vanhoutte PM, The Endothelium: Modulator of Cardiovascular Function, CRC Press, Inc.: Boca Raton, 1990:1–228.
  12. Vanhoutte PM, Félétou M, Taddei S, Endothelium-dependent contractions in hypertension, Br J Pharmacol, 2005;144:449–58.
  13. Feletou M, Vanhoutte PM, EDHF: The Complete Story, CRC Taylor and Francis: Boca Raton, 2006:1–298.
  14. Félétou M, Vanhoutte P, EDHF: where are we now? Arteriosclerosis, thrombosis, and vascular biology, Arterioscler Thromb Vasc Biol, 2006;26:1215–25.
  15. Félétou M, Vanhoutte PM, Endothelium-dependent hyperpolarizations:past beliefs and present facts, Ann Med, 2007;39:495–516.
  16. Vanhoutte PM, Endothelial dysfunction in hypertension, J Hypertens, 1996;14:S83–S93.
  17. Vanhoutte PM, Endothelial dysfunction and atherosclerosis, Eur Heart J, 1997;18:E19–E29.
  18. Vanhoutte PM, Ageing and endothelial dysfunction, Eur Heart J, 2002;4:A8–A17.
  19. Félétou M, Vanhoutte PM, Endothelial dysfunction: a multifaceted disorder, The Wiggers Award Lecture, Am J Physiol Heart Circ Physiol, 2006;291:H985–H1002.
  20. Lüescher TF, Tanner FC, Tschudi MR, Noll G, Endothelial dysfunction in coronary artery disease, Annu Rev Med, 1993;44:395–418.
  21. Vanhoutte PM, Say NO to ET, J Autonom Nervous System, 2000;81:271–77.
  22. Voetsch B, Jin RC, Loscalzo J, Nitric oxide insufficiency and atherothrombosis, Histochemistry and Cell Biology, 2004;122:353–67.
  23. Cohen RA, Shepherd JT, Vanhoutte PM, Vasodilatation mediated by the coronary endothelium in response to aggregating platelets, Bibl Cardiol, 1984;38:35–42.
  24. Houston DS, Shepherd JT, Vanhoutte PM, Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets, Am J Physiol, 1985;248:H389–95.
  25. Houston DS, Shepherd JT, Vanhoutte PM, Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries Role of serotonin, thromboxane A2, and adenine nucleotides, J Clin Invest, 1986;78:539–44.
  26. Shimokawa H, Kim P, Vanhoutte PM, Endothelium-dependent relaxation to aggregating platelets in isolated basilar arteries of control and hypercholesterolemic pigs, Circ Res, 1988;63:604–12.
  27. Shimokawa H, Vanhoutte PM, Angiographic demonstration of hyperconstriction induced by serotonin and aggregating platelets in porcine coronary arteries with regenerated endothelium, J Am Coll Cardiol, 1991;17:1197–1202.
  28. Flavahan NA, Shimokawa H, Vanhoutte PM, Pertussis toxin inhibits endothelium-dependent relaxations to certain agonists in porcine coronary arteries, J Physiol, 1989;408:549–60.
  29. Shimokawa H, Flavahan NA, Vanhoutte PM, Loss of endothelial pertussis toxin-sensitive G-protein function in atherosclerotic porcine coronary arteries, Circulation, 1991;83:652–60.
  30. Rubanyi GM, Romero JC, Vanhoutte PM, Flow-induced release of endothelium-derived relaxing factor, Am J Physiol, 1986;250:H1145–H1149.
  31. Miller VM, Vanhoutte PM, Enhanced release of endotheliumderived factors by chronic increases in blood flow, Am J Physiol, 1988;255:H446–H451.
  32. Davies PF, Flow-mediated endothelial mechanotransduction, Physiological Reviews, 1995;75:519–60.
  33. Busse R, Fleming I, Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces, Trends Pharmacol Sci, 2003;24:24–9.
  34. Yan C, Huang A, Kaley G, Sun D, Chronic high blood flow potentiates shear stress-induced release of NO in arteries of aged rats, Am J Physiol Heart Circ Physiol, 2007;293:H3105–H3110.
  35. Mombouli J-V, Vanhoutte PM, Kinins and Endotheliumdependent relaxations to converting enzyme inhibitors in perfused canine arteries, J Cardiovasc Pharmacol, 1991;18:926–7.
  36. Roves P, Kurz S, Hanjörg J, Drexler H, Role of endogenous bradykinin in human coronary vasomotor control, Circulation, 1995;92:3424–30.
  37. Mombouli JV, Nakashima M, Hamra M, Vanhoutte PM, Endothelium-dependent relaxation and and hyperpolarization evoked by bradykinin in canine coronary arteries: enhancement by exercise-training, Br J Pharmacol, 1996;117:413–18.
  38. Watts K, Beye P, Siafarikas A, et al., Exercise training normalizes vascular dysfunction and improves central adiposity in obese adolescents, J Am Coll Cardiol, 2004;43:1823–7.
  39. Hambrecht R, Adams V, Erbs S, et al., Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase, Circulation, 2003;107:3152–8.
  40. Suvorava T, Lauer N, Kojda G, Physical inactivity causes endothelial dysfunction in healthy young mice, J Am Coll Cardiol, 2004;44:1320–27.
  41. Lauer N, Suvorava T, Rüther U, et al., Critical involvement of hydrogen peroxide in exercise-induced up-regulation of endothelial NO synthase, Cardiovascular Res, 2005;65:254–62.
  42. Gisclard V, Miller VM, Vanhoutte PM, Effect of 17 betaestradiol on endothelium-dependent responses in the rabbit, J Pharmacol Exp Ther, 1988;244:19–22.
  43. Miller VM, Vanhoutte PM, Progesterone and modulation of endothelium-dependent responses in canine coronary arteries, Am J Physiol, 1991;261:R1022–R1027.
  44. Shimokawa H, Lam JY, Chesebro JH, et al., Effects of dietary supplementation with cod-liver oil on endothelium-dependent responses in porcine coronary arteries, Circulation, 1987;76:898–905.
  45. Shimokawa H, Aarhus LL, Vanhoutte PM, Dietary omega-3 polyunsaturated fatty acids augment endothelium-dependent relaxation to bradykinin in porcine coronary microvessels, Br J Pharmacol, 1988;95:1191–6.
  46. Shimokawa H, Vanhoutte PM, Dietary omega-3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries, Am J Physiol, 1989;256:H968–H973.
  47. von Schacky C, Harris WS, Cardiovascular benefits of omega-2 fatty acids, Cardiovascular Research, 2007;73:310–15.
  48. Stockley CS, Wine in moderation: how could and should recent in vitro and in vivo data be interpreted?, Drug Alcohol Rev, 1998;17:365–76.
  49. Dell’Agli M, Buscialà A, Bosisio E, Vascular effects of wine polyphenols, Cardiovascular Res, 2004;63:593–602.
  50. Grassi D, Necozione S, Lipi C, et al., Cocoa reduces blood pressure and insulin resistance and improves endotheliumdependent vasodilation in hypertensives, Hypertension, 2005;46:398–405.
  51. Kuriyama S, Shimazu T, Ohmori K, et al., Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan The Ohsaki Study, JAMA, 2006;296:1255–65.
  52. Sarr M, Chataigneau M, Martnis S, et al., Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats:role of NADPH oxidase, Cardiovascular Research, 2006;71:794–802.
  53. Flemmer AJ, Hermann F, Sudano I, et al., Dark chocolate improves coronary vasomotion and reduces platelet reactivity, Circulation, 2007;116:2376–82.
  54. Das S, Santani DD, Dhalla NS, Experimental evidence for the cardioprotective effects of red wine, Exp Clin Cardiol, 2007;12:5–10.
  55. Taubert D, Roesen R, Lehmann C, et al., Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide, JAMA, 2007;298:49–60.
  56. Lopez-Sepulveda R, Jiménez R, Romero M, et al., Wine - polyphenols improve endothelial function in large vessels of female spontaneously hypertensive rats, Hypertension, 2008;51:1088–95.
  57. Chauhan A, More RS, Mullins PA, et al., Aging-associated endothelial dysfunction in humans is reversed by L-arginine, J Am Coll Cardiol, 1996;28:1796–1804.
  58. Briet M, Collin C, Laurent S, et al., Endothelial function and chronic exposure to air pollution in normal male subjects, Hypertension, 2007;50:970–76.
  59. Budhiraja R, Parthasarathy S, Quan SF, Endothelial dysfunction in obstructive sleep apnoea, J Clin Sleep Med, 2007;3:409–15.
  60. Shimokawa H, Vanhoutte PM, Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and in atherosclerosis, Circ Res, 1989;64:900–14.
  61. Shimokawa H, Vanhoutte PM, Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries, J Am Coll Cardiol, 1989;13:1402–8.
  62. Trochu J, Mital S, Zhang X, et al., Preservation of NO production by statins in the treatment of heart failure, Cardiovascular Research, 2003;60:250–58.
  63. Landmesser U, Bahlmann F, Mueller M, et al., Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans, Circulation, 2005;111:2356–63.
  64. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al., Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy, Euro Heart J, 2006;27:1182–90.
  65. Inoue T, Node K, Statin therapy for vascular failure, Cardiovasc Drugs Ther, 2007;21:281–95.
  66. Van Guilder GP, Hoetzer GL, Dengel DR, et al., Impaired endothelium-dependent vasodilation in normotensive and normoglycemic obese adult humans, J Cardiovasc Pharmacol, 2006;47:310–13.
  67. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al., Endothelial dysfunction in diabetes, Br J Pharmacol, 2000;130:963–74.
  68. Lüscher TF, Raij L, Vanhoutte PM, Endothelium-dependent vascular responses in normotensive and hypertensive Dahl-rats, Hypertension, 1987;9:157–63.
  69. Lüscher TF, Vanhoutte PM, Raij L, Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in salt-induced hypertension of the rat, Hypertension, 1987;9:III- 193/III-197.
  70. Taddei S, Virdis A, Mattei P, et al., Aging and endothelial function in normotensive subjects and patients with essential hypertension, Circulation, 1995;91:1981–7.
  71. Taddei S, Virdis A, Ghiadoni L, et al., Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension, Hypertension, 1997;29:274–9.
  72. Lüscher TF, Vanhoutte PM, Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat, Hypertension, 1986;8:344–8.
  73. Shi Y, Feletou M, Ku DD, et al., The calcium ionophore A23187 induces endothelium-dependent contractions in femoral arteries from rats with streptozotocin-induced diabetes, Br J Pharmacol, 2007;150:624–32.
  74. Hibbert B, Olsen S, O’Brien E, Involvement of progenitor cells in vascular repair, Trends Cardiovasc Med, 2003;13:322–6.
  75. Sata M, Circulating vascular progenitor cells contribute to vascular repair, remodeling, and lesion formation, Trends Cardiovasc Med, 2003;13:249–53.
  76. Dimmeler S, Zeiher AM, Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis?, J Mol Med, 2004;82:671–7.
  77. Lamping K, Endothelial progenitor cells: sowing the seeds for vascular repair, Circ Res, 2007;100:1243-1245.
  78. Lee MYK, Tse HF, Siu CW, et al., Genomic changes in regenerated porcine coronary arterial endothelial cells, ATVB, 2007;27:2443–9.
  79. Shimokawa H, Flavahan NA, Vanhoutte PM, Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries: possible dysfunction of a pertussis toxin-sensitive G protein, Circ Res, 1989;65:740–53.
  80. Borg-Capra C, Fournet-Bourguignon MP, Janiak P, et al., Morphological heterogeneity with normal expression but altered function of G proteins in cultured regenerated porcine coronary endothelial cells, Br J Pharmacol, 1997;122:999–1008.
  81. Fournet-Bourguignon MP, Castedo-Delrieu M, Bidouard JP, et al., Phenotopic and functional changes in regenerated porcine coronary endothelial cells Increased uptake of modified LDL and reduced production of NO, Circ Res, 2000;86:854–61.
  82. Kennedy S, Fournet-Bourguignon M-P, Breugnot C, et al., Cells derived from regenerated endothelium of the porcine coronary artery contain more oxidized forms of Apolipoprotein-B-100 without a modification in the uptake of oxidized LDL, J Vasc Res, 2003;40:389–98.
  83. Boulanger C, Bühler FR, Lüscher TF, Low density lipoproteins impair the release of endothelium-derived relaxing factor from cultured porcine endothelial cells, Abstract, Eur Heart J, 1985;10:331.
  84. Cox DA, Cohen ML, Selective enhancement of 5- hydroxytryptamine-induced contraction of porcine coronary artery by oxidized low-density lipoprotein, J Pharmacol Exp Ther, 1996;276:1095–1103.
  85. Stocker R, Keaney Jr JF, Role of oxidative modifications in atherosclerosis, Physiol Rev, 2004;84:1381–1478.
  86. Stocker R, Keaney Jr JF, New insights on oxidative stress in the artery wall, J Thrombosis & Haemostasis, 2005;3:1825–34.
  87. Li D, Mehta JL, Oxidized LDL, a critical factor in atherogenesis, Cardiovasc Res, 2005;68:353–54.
  88. Chu Y, Alwahdani A, Lida S, et al., Vascular effects of the human extracellular superoxide dismutase R213G variant, Circulation, 2005;112:1047–53.
  89. Brandes RP, Roads to dysfunction: argininase II contributes to oxidized low-density lipoprotein-induced attenuation of endothelial NO production, Circ Res, 2006;99:918–20.
  90. Ryoo S, Lemmon CA, Soucy KG, et al., Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling, Circ Res, 2006;99:951–60.
  91. Ryoo S, Gupta G, Benjo A, et al., Endothelial arginase II: a novel target for the treatment of atherosclerosis, Circ Res, 2008;102.
  92. Vanhoutte PM, Arginine and arginase: eNOS double crossed?, Circ Res, 2008;102:866–8.
  93. Kojda G, Harrison D, Interactions between NO and reactive oxygen species:pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure, Cardiovasc Res, 1999;43:562–71.
  94. Vanhoutte PM, Endothelium-derived free radicals: for worse and for better, J Clin Invest, 2001;107:23–5.
  95. Fleming I, Mohamed A, Galle J, et al., Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCα, Cardiovasc Res, 2005;65:897–906.
  96. Ardigo D, Assimes TL, Fortmann SP, et al., Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease, Physiol Genomics, 2007;31:402–9.
  97. Bechara C, Wang X, Chai H, et al., Growth-related oncogene-α induces endothelial dysfunction through oxidative stress and downregulation of eNOS in porcine coronary arteries, Am J Physiol Heart Circ Physiol, 2007;293:H3088–95.
  98. Herrman J, Saguner AM, Versari D, et al., Chronic proteasome inhibition contributes to coronary atherosclerosis, Circ Res, 2007;101:865–74.
  99. Guns PJ, Assche TV, Verreth W, et al., Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein e-deficient mice with preexisting atherosclerosis, Br J Pharmacol, 2008;153:508–16.
  100. Ross R, Atherosclerosis: an inflammatory disease, N Engl J Med, 1999;340:115-126.